Procare Health launch the first treatment

to prevent and treat HPV-dependent lesions

More than 1.7 million women in Spain over the age of 15 are infected with human papillomavirus (HPV), a sexually transmitted virus.

 

Human papillomavirus (HPV) infection is one of the most common sexually transmitted diseases among the population.In fact, it is estimated that 80% of people have ever suffered. In the case of women, their spread is especially relevant, as it is the most common cause of cervical cancer.While it is true that there is a vaccine for prevention, there are no anti-infection therapies and so far there was no treatment for the prevention of injury once the virus has spread. 

For this reason, and after research studies, Procare Health has developed Papilocare, a new vaginal gel especifically indicated for prevention and treatment of these lesions. 

The results of the Paloma clinical trial, in which 101 HPV positive patientss with low-grade cervical lesions were recruited, showed that 88% of the high-risk HPV positive women have normalized the lesions and 63% of them have cleared the infection after a 6-month treatment period.

"The results of the Paloma clinical trial allow us to state that now we get something we hadn't before: a non-invasive treatment for low-grade cervical lesions caused by HPV", explained Dr. Javier Cortés.